Hims & Hers (NYSE: HIMS) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the ...

OpenAI CEO Sam Altman and Meta both announced $1 million donations, and Amazon and Apple CEO Tim Cook have also reportedly ...

What initially stands out to me about Hims & Hers is the company's distinct branding and feel of luxury, which is evident on ...

Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream.

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Ratings for Hims & Hers Health HIMS were provided by 12 analysts in the past three months, showcasing a mix of bullish and ...

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Cedar Grove Capital Management, an investment management company, released its fourth quarter 2024 investor letter. A copy of ...

BTIG initiated coverage of Hims & Hers with a Buy rating and $35 price target The firm says its likes Hims & Hers because of its ...

Analyst Ryan MacDonald of Needham maintained a Buy rating on Hims & Hers Health (HIMS – Research Report), boosting the price target to ...

Hims has become a leader in the weight loss treatment industry by offering access to men’s health solutions that are both ...

In recent trading, shares of Hims & Hers Health Inc (Symbol: HIMS) have crossed above the average analyst 12-month target price of $25.36, changing hands for $26.63/share. When a stock reaches the ...